PMV Pharmaceuticals Inc
PMVP
Company Profile
Business description
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Contact
400 Alexander Park Drive
Suite 301
PrincetonNJ08540
USAT: +1 609 642-6670
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
54
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Proposed legislation removes health insurance rebates.
stocks
Investors overlooking ASX share’s potential
International expansion is a distraction from valuable local business.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,735.40 | 83.10 | -0.94% |
| CAC 40 | 7,987.49 | 0.00 | 0.00% |
| DAX 40 | 24,307.92 | 357.35 | 1.49% |
| Dow JONES (US) | 49,686.12 | 159.95 | 0.32% |
| FTSE 100 | 10,323.75 | 128.38 | 1.26% |
| HKSE | 25,675.18 | 287.55 | -1.11% |
| NASDAQ | 26,090.73 | 134.41 | -0.51% |
| Nikkei 225 | 60,815.95 | 593.34 | -0.97% |
| NZX 50 Index | 12,826.07 | 63.15 | 0.49% |
| S&P 500 | 7,403.05 | 5.45 | -0.07% |
| S&P/ASX 200 | 8,505.30 | 72.60 | -0.85% |
| SSE Composite Index | 4,131.53 | 3.86 | -0.09% |